Company intelligence / Profile preview
Liveome
Suwon-si, Gyeonggi-do, South Korealiveome.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Liveome has completed a Phase 1 clinical trial in Australia for its gene-recombinant microbiome drug, LIV001, targeting IBD. Preclinical studies have confirmed efficacy in acute and chronic enteritis. The company is expanding its pipeline to include anticancer candidates.[4][5]
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Live biotherapeutic products (LBPs)Gene-recombinant microbiome therapeuticsMicrobial cell therapies[4][5][6]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Luina Bio (Australia): CDMO partner supplying raw materials for clinical manufacturing of LBPs [5]Quay Pharma / SGS Quay Pharma UK : CDMO partner responsible for finished product manufacturing and formulation development [5][6]
Beyond the preview
Go deeper on Liveome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liveome.